Cegedim Health Data

[WORD FROM OUR EXPERTS] 🎙️"As a Global Account Director at Cegedim Health Data, I combine 20 years of experience in the healthcare ecosystem with strong client focus to develop value-added projects. My proactive, caring approach allows me to forge solid partnerships by aligning a team of experts around my clients.” Elodie Minnaert   #Expertise #Sales #RWE #CegedimCareers #Realworlddata #rwd #Realworldevidence #rwe

"HEOR harnesses the benefits of patient-centered research, which includes understanding the patients’ real-world journeys, preferences, and experiences, allowing researchers to gain insights into what patients consider to be a “success” in treatment and knowing what side effects they are willing to tolerate as part of treatment". In fact, as a key component of HEOR, RWE has been named the #1 trend by the Professional Society for Health Economics and Outcomes Research (ISPOR) in its three most recent “Top 10 HEOR Trends” biannual reports. Check out this interview with ISPOR’s CEO Rob Abbott, in which he shares his thoughts on the critical importance of establishing a culture of transparency for RWE studies and ISPOR’s new initiative to facilitate that goal. Gilles Paubert, Global Head of Cegedim Health Data #realworlddata #rwd #realworldevidence #rwe #HEOR #ISPOR

📢 NEWS 📢 New study based on THIN® data published in @Clinical cardiology Topic 🔎 Characteristics of Patients With Atherosclerotic Cardiovascular Disease in Belgium and Current Treatment Patterns for the Management of Elevated LDL-C Levels 🎯 Objective: To describe the current treatment landscape in Belgium, hypothesizing that lipid management in patients with ASCVD remains inadequate and aiming to understand the reasons. 🧐Conclusions: The study emphasizes the importance of developing strategies to help patients achieve their LDL-C goals, with a focus on supporting the implementation of combination LLT in routine clinical practice. Learn more 👉 https://lnkd.in/gffBmetV #RWD #RWE #realworlddata #realworldevidence Impact of LLT on the proportion of patients with ASCVD per LDL-C range 👇

Digital therapeutics (DTx) is a category of digital health that generated a lot of “buzz” and grew rapidly since it arrived on the scene in 2017. DTx startups and innovations – and investor interest in them, including pharma partnerships – reached their peak at the height of the COVId-19 pandemic, but began to decline in 2022, in part due to challenges with securing clinician uptake and reimbursement for DTx products. One of the most common barriers to higher adoption of DTx has been a lack of evidence to back up clinical efficacy claims. Now, at the dawn of a “second coming” for these software-based medical technologies, DTx manufacturers are more aware than ever of the need to marshal up strong evidence to support uptake by clinicians and payers – and RWE studies can do a lot of “heavy lifting” here. In the EU, France and Germany are leading the way for DTx by evolving their regulatory frameworks and updating reimbursement models to integrate these technologies into the healthcare ecosystem. There is also a renewed interest by pharma companies in teaming up with DTx developers as a way to add value to pharmacologic interventions. Between these two avenues of advances, the future of DTx looks promising again. Gilles Paubert, Global Head of Cegedim Health Data #realworlddata #rwd #realworldevidence #rwe

At the 2nd Annual Real-World Data and Market Access Conference by MarketsandMarkets, I had the pleasure of presenting our Real-World Data network, THIN®, together with my colleagues on behalf of Cegedim Health Data. Many thanks to the organizers for the successful event and to all participants for the engaging and inspiring exchange! If you are interested in a more in-depth discussion about THIN®, I would be happy to connect with you at any time. ______________ Auf der 2. Jahreskonferenz für Real-World-Daten und Market Access von MarketsandMarkets hatte ich gemeinsam mit meinen Kollegen die Gelegenheit, im Namen von Cegedim Health Data unser Real-World-Datennetzwerk THIN® vorzustellen. Vielen Dank an die Veranstalter für das gelungene Event und an alle Teilnehmenden für den anregenden und inspirierenden Austausch! Wenn Sie Interesse an weiteren Informationen zu THIN® haben, freue ich mich jederzeit über Ihre Kontaktaufnahme.

📢 NEWS 📢 New study based on THIN® data published in @Acta Diabetologica Topic 🔎 Generalizability and treatment with sodium-glucose co-transporter-2 inhibitors (SGLT2i) among patients with type 2 diabetes: an assessment using an Italian primary care database 🎯 Objective: To assess the proportions of type 2 diabetes (T2D) subjects meeting cardiovascular outcome trials (CVOTs) criteria for sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and estimate SGLT2i utilization, along with associated demographic and clinical characteristics, in a primary care Italian setting. 🧐Conclusions: Significant variability in the proportion of T2D subjects meeting SGLT2i CVOT inclusion criteria. Low SGLT2i prescription rates in the Italian primary care setting, along with substantial demographic and clinical differences between SGLT-2i users and T2D eligible patients, emphasize the need for targeted interventions to optimize the use of these medications in primary care settings. Learn more 👉https://lnkd.in/e4Jij3tQ Ippazio Cosimo Antonazzo, Davide Rozza, Paolo Angelo Cortesi, Carla Fornari, Elena Zanzottera Ferrari, Claire PARIS, Caroline Eteve Pitsaer, Marco Gnesi, Silvia Mele, Marco D’Amelio, Anna Rita Maurizi, Pasquale Palladino, Lorenzo G Mantovani & Giampiero Mazzaglia. #RWD #RWE #realworlddata #realworldevidence #Diabetes #SGLT2i Multivariable logistic regression to assess demographic and clinical factors associated with prescribing SGLIT2i vs. other antidiabetic therapies in patients potentially eligible to CVOTs trials 👇

The role of AI in the pharma industry keeps assuming new dimensions, with AI tools creating positive impact and value by boosting operational efficiencies and accelerating R&D. In the RWD realm, AI-driven solutions are surfacing data insights that would be challenging to obtain manually, using human bandwidth alone. When leveraged together with predictive capabilities, those insights have the potential to forecast patients’ disease progression over time while using a given drug or treatment. Miruna Sasu, CEO of COTA, which specializes in oncology RWD, says: “In the long run, a drug candidate would come out of discovery and go right into a real-world model and be tested against patient populations to see if it’s going to work and by how much. The technology is there to allow for that.” Do you share Miruna’s optimism? Or do you have a different view on how RWD and AI technologies could impact the life sciences? We’d love to hear your thoughts. Gilles Paubert, Global Head of Cegedim Health Data #realworlddata #rwd #realworldevidence #rwe

🛎 Last Call to meet the Cegedim Health Data team at the 2nd annual MarketsandMarkets™ Real-world Evidence and Market Access Conference, held next week in Freiburg, from October 14-15, 2024. 👉 Elodie Minnaert, Julius Verhagen and Ralf Patsch are in the starting-blocks to meet you and discuss about your evidence generation projects. #realworlddata #rwd #realworldevidence #rwe #MarketAccess

Developments in the RWE space – such as new methodologies, use cases, and technological advancements – are continuing to evolve. This relentless innovation speaks to the increasing recognition of RWD and RWE solutions as critical tools in pharma innovation, regulatory science, and healthcare decisions-making. According to a recent forecast by Future Market Insights, the global RWE solutions market is expected to reach $110 billion by 2032 – an increase of more than $67 billion over the course of a decade. The report places Cegedim Health Data as a leading competitor in this space and we are proud to have earned this recognition with our commitment to providing high-quality, standardized, consistently reliable RWD. Gilles Paubert, Global Head of Cegedim Health Data #realworlddata #rwd #realworldevidence #rwe

🛎 Cegedim Health Data is gold sponsor at the 2nd annual MarketsandMarkets™ Real-world Evidence and Market Access Conference, held in Freiburg from October 14-15, 2024. Elodie Minnaert Godon , Julius Verhagen and Ralf Patsch will attend the event. 👉 A great opportunity to meet you face-to-face to discuss about your evidence generation projects. #realworlddata #rwd #realworldevidence #rwe #MarketAccess